Skip to main navigation

Investors + Newsroom
Culture + Careers

Who We Are

Who We Are
Science & Innovation

Science & Innovation
Therapeutic Pipeline

Therapeutic Pipeline
Patients & Families

Patients & Families

Search
Investors + Newsroom
Culture + Careers

Events & Presentations

Overview
News
Events + Presentations
Stock Information
- Analyst Coverage
Sec Filings
Corporate Governance
Shareholder Services

Featured Presentations

Corporate Presentation
RGX-202 Topline Pivotal Results

Data Publications

March 2026: RGX-202 Oral Presentation At The Muscular Dystrophy Association Clinical & Scientific Conference 1.7 MB

March 2026: RGX-202 Poster Presentation At The Muscular Dystrophy Association Clinical & Scientific Conference 16.5 MB

October 2025: RGX-202 Oral Presentation at World Muscle Society Annual Congress 594.2 KB

October 2025: RGX-202 Poster Presentation at World Muscle Society Annual Congress 336.1 KB

August 2025: 2-Year Sura-vec (ABBV-RGX-314) Results in Non-Proliferative Diabetic Retinopathy 601.3 KB

June 2025: RGX-202: Affinity Duchenne® New Phase I/II Interim Functional Data 1.2 MB

November 2024 RGX-202: AFFINITY DUCHENNE® Pivotal Trial And Interim Functional Data 2.1 MB

Upcoming Events

Oct 20, 2026 at 1:00 PM EDT

Sura-vec in Wet AMD: Clinical Program Overview and Expert Perspectives

Click here for webcast

Add to Google Calendar

Past Events

Sep 16, 2026 at 8:30 AM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Click here for webcast

Sep 15, 2026 at 8:30 AM EDT

Baird 2026 Global Healthcare Conference

click here for webcast

Aug 06, 2026 at 8:00 AM EDT

Q2 2026 REGENXBIO Inc. Earnings Conference Call

Click here for webcast

May 26, 2026 at 9:30 AM EDT

Stifel 2026 Virtual Ophthalmology Forum

May 20, 2026 at 9:30 AM EDT

2026 RBC Capital Markets Global Healthcare Conference

Click here for webcast

May 14, 2026 at 8:00 AM EDT

REGENXBIO: Topline Results from Pivotal Trial of RGX-202

Click here for webcast

Contact Us

Stay connected on REGENXBIO programs and our commitment to patients.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

Contact Us

Terms and Conditions

Privacy Policy

© 2026 Regenxbio Inc. • "NAV®" is a registered trademark of REGENXBIO Inc. • All Rights Reserved